Tech Company Financing Transactions
HiberCell Funding Round
Arch Venture Partners, Bristol-Myers Squibb and Hercules Technology Growth Capital joined a $67.4 million Series B funding round for HiberCell. The financing round was announced on 5/20/2021.
Transaction Overview
Company Name
Announced On
5/20/2021
Transaction Type
Debt
Venture Equity
Venture Equity
Amount
$67,400,000
Round
Series B
Investors
Proceeds Purpose
HiberCell will use the proceeds of the Series B financing and debt facility to support the clinical development of novel therapeutics targeting stress biology and innate immunity to address the role these play in prevention of cancer recurrence and metastasis.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
619 West 54th St. 8th Floor
New York, NY 10019
USA
New York, NY 10019
USA
Phone
Website
Email Address
Overview
HiberCell is the first company exclusively focused on tumor dormancy detection and therapeutics. The company is developing first-in-class therapeutics that target dormant disseminated tumor cells (DTCs) from solid and liquid cancers, with the ultimate goal of preventing cancer relapse and metastasis.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Financial Officer
Joseph Talamo
President
Alan Rigby
Vice President
Nandita Bose
Vice President
Michele Gargano
Vice President
Mark Mulvihill
Vice President
Patricia Oliver
Vice President
Savi Ramurthy
Vice President
David Surguladze
VP - Bus. Development
Ari Nowacek
Browse more venture capital transactions:
Prev: 5/20/2021: Icon Source venture capital transaction
Next: 5/20/2021: daring venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs